Loading company
Aytu Biopharma, Inc.
AYTU · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$2.15-5.7%Sep 29 close
- 1M
- -4.4%
- 6M
- -18.4%
- 1Y
- +14.4%
- 5Y
- -96.6%
AYTU · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$2.15-5.7%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $16.1M | $15.1M | +6.42% |
| Profit | -$15K | -$19.8M | +99.92% |
| Profit per share | -$0.53 | $0.09 | -670.51% |
| Free Cash Flow | $4.4M | $2.8M | +57.72% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
A short summary of each call — what the quarter showed, what management expects and whether they delivered on what they said last time — with the full transcript underneath.
Releases land after the close or before the open, so the move is the session that follows.
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company’s prescription products include EXXUA® (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company’s medications through best-in-class patient access programs that help to enable optimal patient outcomes.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Aytu Biopharma, Inc.’s Item 2.02 8-K filed September 22, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
Call summaries are part of Pro
A two-minute read of every Aytu Biopharma, Inc. earnings call: the numbers that mattered, what management expects, whether they delivered on last quarter’s outlook, and what analysts asked that went unanswered.
See one first on , , or — open to everyone.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.